@article { author = {Andisheh-Tadbir, Azade and Mardani, Maryam and Malekzadeh, Mahyar and Amirbeigi Tafti, Tayebe and Khademi, Bijan}, title = {Galectin-3 Serum Levels Could Help Clinicians Screen for Salivary Gland Tumor Patients}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {19}, number = {3}, pages = {689-692}, year = {2018}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {10.22034/APJCP.2018.19.3.689}, abstract = {analysis was performed on serum specimens from 105 patients with salivary gland cancer and 56 healthy persons.Methods: Enzyme-linked immunosorbent assay (ELISA) was used to measure levels of galectin-3 (GAL-3). Serumlevels were compared between patients with salivary gland tumors and healthy control. A total of 105 patients wereenrolled in the study (55 men, 50 women). Result: Mean age was45.5 years. Thirty-nine patients with malignant and66 cases with benign tumors were compared with 56 healthy participants with a mean age of 51.7. No statisticallysignificant differences were observed when comparing GAL-3 serum levels between malignant and benign salivary glandtumor patients, but a statistically significant difference was found between case and control patients with p-values of0.02. Serum levels of galectin-3 protein were elevated in patients with salivary gland cancer compared with the healthypopulation. Conclusion: The difference between benign and malignant tumor patients was significant, but revealedno clinic pathological characteristics in malignant tumors. To the best of the authors’ knowledge, this is the first timea study suggests that GAL-3 serum levels could help clinicians screen for salivary gland cancer.}, keywords = {Salivary Gland,cancer,Serum,Galectin-3, biomarker}, url = {https://journal.waocp.org/article_57599.html}, eprint = {https://journal.waocp.org/article_57599_61e2ea8b7d9b412c2454ca85973e8a35.pdf} }